肺癌Lung cancer,也称为肺癌lung carcinoma(因为大约 98-99% 的肺癌是癌),是一种恶性肺部肿瘤,其特征是肺组织中的细胞生长不受控制。肺癌来源于转化的恶性细胞,这些细胞起源于上皮细胞,或来源于由上皮细胞组成的组织。其他肺癌,例如罕见的肺部肉瘤,是由间充质细胞产生的结缔组织(即神经、脂肪、肌肉、骨骼)的恶性...
Importantly, the poor prognosis associated with coactivation of ITF-1 and NKX2-8 was validated in 2 other independent clinical data sets. Furthermore, lung cancer cell lines showing coactivation of the TTF-1 and NKX2-8 pathways were shown to exhibit resistance to cisplatin, the standard of ...
昨天,肺癌国际著名杂志《Lung Cancer》发布了一篇劲爆文章,初步揭示了MET通路异常用PD1可能有奇效的情况。MET通路异常包括点突变(如14跳跃突变等)、扩增、重排和过表达。在肺癌中以MET突变、扩增和过表达多见。该研究中的主要结论有三: 相比MET阴性...
ttf-1在小细胞肺癌与非小细胞肺癌中的表达及鉴别诊断意义的meta分析 expression of ttf-1 in cell lung cancer and non-small cell lung cancer and differential diagnosis meaning by meta-static,ttf-1在小细胞肺癌与非小细胞肺癌中的表达及鉴别诊断意义的meta分析 expression of ttf-1 in cell lung cancer an...
L. Lung cancer in nonsmokers. Cancer 53, 1214–1221 (1984). Article CAS PubMed Google Scholar Muscat, J. E. & Wynder, E. L. Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett. 88, 1–5 (1995). Article CAS PubMed Google Scholar Stockwell, H. G. et ...
基于此,AME出版社挑选了近年来发表的肺癌诊疗领域有挑战的临床病例汇编成书——Case Reports in Lung Cancer(中文译名《肺癌病例报告》)。这些病例既包括肺癌脑膜转移的药物治疗、罕见突变如EGFR-RAD51的药物治疗以及罕见合并症如肿瘤相关脑降解的处理;也包括基于ctDNA监测的新型药物治疗策略,以及药物治疗带来的罕见并发...
lung cancerThyroid transcription factor‐1 (TTF‐1, encoded by the gene) is highly expressed in small‐cell lung carcinoma (SCLC) and lung adenocarcinoma (LADC), but how its functional roles differ between SCLC and LADC remains to be elucidated. Here, we compared the genome‐wide distributions...
Clin. Cancer Res. 15, 5216–5223 (2009). Article CAS PubMed PubMed Central Google Scholar Yoshida, A. et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72, 309–315 (2011). Article PubMed Google Scholar ...
吸烟被美国癌症协会(American Cancer Society)认定为首要风险因素,预计到2035年,吸烟将占肺癌病例的81%。肺癌是由上皮细胞发展而来的恶性肿瘤,是肺部最常见的恶性肿瘤。起源于此部位的肺癌被称为原发性肺癌,区别于那些通过转移扩散到肺部的肺癌。原发性肺癌可分为两大组织病理类型:小细胞癌和非小细胞癌,其中以非小...
肺癌(lung cancer)临床试验常用指标 总生存期(Overall Survival, OS):总生存期常被用于大型随机试验的首要指标。它的测量很直观,是指患者从进入随机分组到患者因任何原因死亡的时间。由于OS直接体现了患者的生存获益,并且可以被准确测量,一直被认为是衡量疗效的金标准。